p53 protein expression in breast cancer as related to histopathological characteristics and prognosis - PubMed (original) (raw)
p53 protein expression in breast cancer as related to histopathological characteristics and prognosis
P Lipponen et al. Int J Cancer. 1993.
Abstract
Formalin-fixed, paraffin-embedded biopsies of 193 women with primary breast cancer followed-up for over 10 years were analysed immunohistochemically for the expression of p53 protein. Altogether, 58% (113/193) of the tumors were positive for p53 protein. Over-expression of p53 was associated with the ductal type, high-grade tumors, dense stromal inflammatory cell infiltrate, high S-phase fraction, high mitotic frequency and high values of the nuclear factors. In univariate analysis, intense p53 over-expression predicted a poor outcome, whereas a short recurrence-free survival (RFS) was related to p53 negativity. In axillary lymph-node-negative (ANN) tumors, p53 negativity was related to short RFS, and in axillary lymph-node-positive (ANP) tumors this inverse relationship was statistically significant. In Cox's analysis, p53 protein over-expression had no independent prognostic value comparable with the well-established prognostic factors. However, p53 protein accumulation was an independent indicator of long RFS in the entire cohort, in ANP tumors and in rapidly proliferating tumors. The results indicate a dual role for p53 protein over-expression in breast cancer prognosis. The low survival probability associated with intensively p53-positive tumors is probably related to rapid cancer-cell proliferation, whereas the long RFS of p53-positive tumors might be explained by the development of circulating antibodies to p53 protein. The role of p53 protein in breast cancer is incompletely understood, and the p53 gene should be subjected to detailed analysis of specific mutations.
Similar articles
- Expression of p53 protein has no independent prognostic value in breast cancer.
Pietiläinen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma VM, Syrjänen K. Pietiläinen T, et al. J Pathol. 1995 Nov;177(3):225-32. doi: 10.1002/path.1711770303. J Pathol. 1995. PMID: 8551383 - Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.
Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL. Allred DC, et al. J Natl Cancer Inst. 1993 Feb 3;85(3):200-6. doi: 10.1093/jnci/85.3.200. J Natl Cancer Inst. 1993. PMID: 8423624 - c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer.
Lipponen HJ, Aaltomaa S, Syrjänen S, Syrjänen K. Lipponen HJ, et al. Anticancer Res. 1993 Jul-Aug;13(4):1147-52. Anticancer Res. 1993. PMID: 8102517 - p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis.
Pellikainen MJ, Pekola TT, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM. Pellikainen MJ, et al. J Clin Pathol. 2003 Mar;56(3):214-20. doi: 10.1136/jcp.56.3.214. J Clin Pathol. 2003. PMID: 12610102 Free PMC article. - p53 as an independent prognostic marker in lymph node-negative breast cancer patients.
Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, Di Fronzo G, Veronesi U. Silvestrini R, et al. J Natl Cancer Inst. 1993 Jun 16;85(12):965-70. doi: 10.1093/jnci/85.12.965. J Natl Cancer Inst. 1993. PMID: 8496982
Cited by
- P53 protein in 204 patients with primary breast carcinoma--immunohistochemical detection and clinical value as a prognostic factor.
Göhring UJ, Scharl A, Heckel C, Ahr A, Crombach G. Göhring UJ, et al. Arch Gynecol Obstet. 1995;256(3):139-46. doi: 10.1007/BF01314642. Arch Gynecol Obstet. 1995. PMID: 7574906 - The p53-estrogen receptor loop in cancer.
Berger C, Qian Y, Chen X. Berger C, et al. Curr Mol Med. 2013 Sep;13(8):1229-40. doi: 10.2174/15665240113139990065. Curr Mol Med. 2013. PMID: 23865427 Free PMC article. Review. - Analysis of clinicopathological characteristics and prognostic factors in 54 metaplastic breast carcinoma patients from northwest China.
Du J, Wu S, Liu J, Guo B, Li J, Li W, Zhang Y, Song H, Shu W, Li Z, Zhu X. Du J, et al. Cytojournal. 2024 Sep 18;21:31. doi: 10.25259/Cytojournal_15_2024. eCollection 2024. Cytojournal. 2024. PMID: 39411170 Free PMC article. - The clinical significance of p53 aberrations in human tumours.
Bosari S, Viale G. Bosari S, et al. Virchows Arch. 1995;427(3):229-41. doi: 10.1007/BF00203389. Virchows Arch. 1995. PMID: 7496591 Review. - TP53 alterations in atypical ductal hyperplasia and ductal carcinoma in situ of the breast.
Chitemerere M, Andersen TI, Holm R, Karlsen F, Børresen AL, Nesland JM. Chitemerere M, et al. Breast Cancer Res Treat. 1996;41(2):103-9. doi: 10.1007/BF01807155. Breast Cancer Res Treat. 1996. PMID: 8944328
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous